Journal of Clinical Oncology, Vol 10, 304-310, Copyright © 1992 by American Society of Clinical Oncology

ARTICLES

Tamoxifen and the isomers of 4-hydroxytamoxifen in tamoxifen-resistant tumors from breast cancer patients

CK Osborne, VJ Wiebe, WL McGuire, DR Ciocca and MW DeGregorio
Department of Medicine, University of Texas Health Science Center, San Antonio 78284-7884.

PURPOSE: The antiestrogen tamoxifen is effective in therapy for breast cancer. However, its use is limited by the eventual development of acquired tamoxifen resistance in many patients. The mechanisms responsible for tamoxifen resistance remain unknown; loss of estrogen receptor (ER), selection of hormone-independent breast cancer clones, or alterations in serum tamoxifen levels after long-term use do not explain acquired resistance in most patients. Using an experimental model in which human breast cancer cells develop resistance in athymic mice treated with tamoxifen, we have recently shown that acquired resistance is associated with markedly reduced cellular concentrations of tamoxifen and by isomerization of the trans-4-hydroxy metabolite to the less potent cis isomer. MATERIALS AND METHODS: Using a sensitive high-performance liquid chromatography (HPLC) assay, we have now measured levels of tamoxifen and its major metabolites in a series of 14 tumors from patients treated with tamoxifen. The duration of therapy ranged from 1 month to 6 years. RESULTS: Tumor tamoxifen levels varied over a wide range. Low concentrations were observed in tumors from eight patients, all demonstrating progressive disease at the time of biopsy after a minimum duration of treatment of 6 months. Six tumors had moderate to high tamoxifen levels, two from patients responding to tamoxifen, one from a patient with stable disease, and three from patients with disease progression. Both the cis and trans isomers of the potent antiestrogenic metabolite 4-hydroxy-tamoxifen were detected in 11 tumors. Six tumors had high ratios of the cis to trans isomer (1.10:2.06), all from patients not responding to tamoxifen. The five tumors with low cis:trans ratios included the two tumors from responding patients and three from patients with progression. All but one of the 11 nonresponding patients had either a low tumor tamoxifen level, a high cis:trans ratio, or both. CONCLUSION: This study clearly demonstrates a wide range of tumor tamoxifen levels and accumulation of the less antiestrogenic cis isomer of 4-hydroxytamoxifen in some patients on tamoxifen therapy. Additional study is necessary to determine if these metabolic profiles are related to the development of tamoxifen resistance.

This article has been cited by other articles:

				F Gadal, A Starzec, C Bozic, C Pillot-Brochet, S Malinge, V Ozanne, J Vicenzi, L Buffat, G Perret, F Iris, et al. Integrative analysis of gene expression patterns predicts specific modulations of defined cell functions by estrogen and tamoxifen in MCF7 breast cancer cells J. Mol. Endocrinol., February 1, 2005; 34(1): 61 - 75. [Abstract] [Full Text] [PDF]

				M. Becker, A. Sommer, J. R. Kratzschmar, H. Seidel, H.-D. Pohlenz, and I. Fichtner Distinct gene expression patterns in a tamoxifen-sensitive human mammary carcinoma xenograft and its tamoxifen-resistant subline MaCa 3366/TAM Mol. Cancer Ther., January 1, 2005; 4(1): 151 - 170. [Abstract] [Full Text] [PDF]

				H. K. Crewe, L. M. Notley, R. M. Wunsch, M. S. Lennard, and E. M. J. Gillam Metabolism of Tamoxifen by Recombinant Human Cytochrome P450 Enzymes: Formation of the 4-Hydroxy, 4'-Hydroxy and N-Desmethyl Metabolites and Isomerization of trans-4-Hydroxytamoxifen Drug Metab. Dispos., August 1, 2002; 30(8): 869 - 874. [Abstract] [Full Text] [PDF]

				D. P. McDonnell, C. E. Connor, A. Wijayaratne, C.-y. Chang, and J. D. Norris Definition of the Molecular and Cellular Mechanisms Underlying the Tissue-selective Agonist/Antagonist Activities of Selective Estrogen Receptor Modulators Recent Prog. Horm. Res., January 1, 2002; 57(1): 295 - 316. [Abstract] [Full Text] [PDF]

				R. Clarke, F. Leonessa, J. N. Welch, and T. C. Skaar Cellular and Molecular Pharmacology of Antiestrogen Action and Resistance Pharmacol. Rev., March 1, 2001; 53(1): 25 - 72. [Abstract] [Full Text] [PDF]

				E. S. Lee, J. M. Schafer, K. Yao, G. England, R. M. O’Regan, A. D. L. Reyes, and V. C. Jordan Cross-Resistance of Triphenylethylene-type Antiestrogens but not ICI 182,780 in Tamoxifen-stimulated Breast Tumors Grown in Athymic Mice Clin. Cancer Res., December 1, 2000; 6(12): 4893 - 4899. [Abstract] [Full Text]

				S. R. D. Johnston, I. M. Boeddinghaus, S. Riddler, B. P. Haynes, I. R. Hardcastle, M. Rowlands, R. Grimshaw, M. Jarman, and M. Dowsett Idoxifene Antagonizes Estradiol-dependent MCF-7 Breast Cancer Xenograft Growth through Sustained Induction of Apoptosis Cancer Res., August 1, 1999; 59(15): 3646 - 3651. [Abstract] [Full Text] [PDF]

				H. Dotzlaw, E. Leygue, P. Watson, and L. C. Murphy The Human Orphan Receptor PXR Messenger RNA Is Expressed in Both Normal and Neoplastic Breast Tissue Clin. Cancer Res., August 1, 1999; 5(8): 2103 - 2107. [Abstract] [Full Text] [PDF]

				F. A. Beland, L. P. McDaniel, and M. M. Marques Comparison of the DNA adducts formed by tamoxifen and 4-hydroxytamoxifen in vivo Carcinogenesis, March 1, 1999; 20(3): 471 - 477. [Abstract] [Full Text] [PDF]

				D. Liu and K. A. Bachmann An Investigation of the Relationship Between Estrogen, Estrogen Metabolites and Blood Cholesterol Levels in Ovariectomized Rats J. Pharmacol. Exp. Ther., July 1, 1998; 286(1): 561 - 568. [Abstract] [Full Text]

				J. I. Macgregor and V. C. Jordan Basic Guide to the Mechanisms of Antiestrogen Action Pharmacol. Rev., June 1, 1998; 50(2): 151 - 196. [Abstract] [Full Text] [PDF]

				M. W. Dudley, C. Q. Sheeler, H. Wang, and S. Khan Activation of the human estrogen receptor by the antiestrogens ICI 182,780 and tamoxifen in yeast genetic systems: Implications for their mechanism of action PNAS, March 28, 2000; 97(7): 3696 - 3701. [Abstract] [Full Text] [PDF]